Verge HealthTech Fund

www.verge.fund

VCMatch tracks Verge HealthTech Fund as an investor focused on Digital Health, Medtech, and Enterprise SaaS companies, Seed and Series A rounds, and Global markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Seed, Series A

Focus Areas

Digital Health, Medtech, Enterprise SaaS

Geography

Global

Investment Thesis

Verge HealthTech invests early and partners actively with founders building technology that amplifies and transforms healthcare. They prioritise companies that make healthcare more accessible, higher quality and more efficient, with a thesis that healthtech is the key to extending healthspan for all and that technology can ‘connect and extend traditional health sectors’ to reach billions. The firm focuses on helping companies cross the chasm from early to growth stages through hands-on operator support, global networks and portfolio synergies.

Is Verge HealthTech Fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Verge HealthTech Fund is most relevant for founders raising Seed and Series A rounds in Digital Health, Medtech, Enterprise SaaS, and AI/ML, especially across Global.

Focus statement

Stage-focused: Seed to Series A, geo-agnostic. Sector-focused: healthtech across AI & data analytics, next-gen diagnostics, smart devices, digital health platforms, digital therapeutics and healthcare SaaS. Their stated focus: "We invest in transformative technology that makes healthcare more accessible, better in quality, and more efficient."

Value Add

Active, operator-driven approach: team made up of founders and healthtech operators who "actively partner with founders crossing the chasm from early to growth stage."
Portfolio synergies and hands-on support: explicit emphasis on collaboration across R&D, commercial distribution and clinical trials within their portfolio.
Global ecosystem and geo-agnostic investing: access to a "global network of leading companies, investors, and institutions" and a stated "Geo - Agnostic" mandate.
Stage specialization: clear Seed to Series A remit, filling an identified gap for early-stage healthtech capital.
Deep domain conviction: consistent, repeated focus on healthtech as the fastest-growing healthcare subsector and as the means to "extend healthspan for all."